Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Overview

The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19 CAR(chimeric antigen receptor)-T cell therapies are efficient for patients with B-cell hematologic malignancies. As for T-cell hematologic malignancies, CD7 is a promising target expressed on most malignant T cells. The outcome of CD-7 CAR-T cell therapy pre-clinical experiments is cheerful.however, how to select the functional T cells from the malignant T cells is a challenge. In addition to this, auto-CAR-T cell therapy is not affordable for the majority of patients. Using T cells aphesis from healthy donors edited to avoid rejection of the host as the material of anti-CD7 universal CAR-T cells could be accessible and affordable, which is adapted for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies.

Full Title of Study: “Anti-CD7 Universal CAR-T Cells for CD7+ T/NK Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 1, 2022

Interventions

  • Biological: CD7 UCAR-T cells
    • Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg
  • Drug: Fludarabine
    • 30mg/m^2 per day for 6 days
  • Drug: Cytoxan
    • 600mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline
  • Drug: Melphalan
    • 50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline

Arms, Groups and Cohorts

  • Experimental: anti-CD7 UCAR-T cells
    • After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD7 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated

Clinical Trial Outcome Measures

Primary Measures

  • the anti-tumor efficiency of anti-CD7 UCAR-T cells
    • Time Frame: 4 weeks after infusion
    • ratio of bone marrow blast cells and/or the measurable lesion size and standralized uptake value

Secondary Measures

  • the long-term efficiency of anti-CD7 UCAR-T cells
    • Time Frame: 3 and 6 months after infusion
    • ratio of bone marrow blast cells and/or the measurable lesion size and standralized uptake value

Participating in This Clinical Trial

Inclusion Criteria

  • 1. Diagnosis of recurrent T-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease, Extranodal NK/T cell lymphoma, Mycosis fungoides/ Sezary Syndrome Stage IIB or higher)) 2. CD7-positive tumor (≥20% CD7 positive blasts by flow cytometry or immunohistochemistry (tissue)) 3. Hgb ≥ 7.0 (can be transfused) 4. Life expectancy greater than 12 weeks 5. Informed consent explained to, understood by and signed by the patient/guardian. Patient/guardian is given a copy of informed consent. Exclusion Criteria:

1. Pregnant or lactating. 2. Tumor in a location where enlargement could cause airway obstruction (per investigator discretion). 3. Active infection with HIV or HTLV. 4. Clinically significant viral infection or uncontrolled viral reactivation of EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BK-virus, or HHV(human herpesvirus)-6. 5. Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT, per investigator discretion. Cardiac echocardiography with LVSF (left ventricular shortening fraction)<30% or LVEF(left ventricular ejection fraction)<50%; or clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart Association) III or IV (Confirmation of absence of these conditions on echocardiogram within 12 months of treatment). 6. CNS abnormalities: Presence of CNS(central nervous system)-3 disease defined as detectable cerebrospinal blast cells in a sample of CSF(cerebrospinal fluid) with ≥ 5 WBC( white blood cell)s per mm3 (unless negative by the Steinherz/Bleyer algorithm); Presence of any CNS disorder such as an uncontrolled seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Xinqiao Hospital of Chongqing
  • Collaborator
    • Gracell Biotechnology Shanghai Co., Ltd.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Xi Zhang, MD, Chef of Hematology Department – Xinqiao Hospital of Chongqing
  • Overall Official(s)
    • Xi Zhang, MD, Principal Investigator, Xinqiao Hospital of Chongqing
  • Overall Contact(s)
    • Xi Zhang, MD, +8613808310064, zhangxxi@sina.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.